The M3 muscarinic receptor i3 domain confers oxidative stress protection on calcium regulation in transfected COS-7 cells

Aging Cell

Volumn 3, Issue 5, 2004, Pages 263-271

  Joseph, James A ^a   Fisher, Derek R ^a   Carey, Amanda ^a   Szprengiel, Aleksandra ^a  

^a TUFTS UNIVERSITY   (United States)

Author keywords

Calcium regulation; Chimeric; COS 7 cells; Dopamine; Muscarinic receptor; Oxidative stress

Indexed keywords

ANTIOXIDANT; CALCIUM ION; MUSCARINIC M1 RECEPTOR; MUSCARINIC M2 RECEPTOR; MUSCARINIC M3 RECEPTOR; MUSCARINIC M4 RECEPTOR; OXOTREMORINE; RECEPTOR SUBTYPE;

AMINO ACID SEQUENCE; ANIMAL CELL; ARTICLE; CALCIUM HOMEOSTASIS; CALCIUM TRANSPORT; CELL PROTECTION; CELL STRAIN COS7; CONTROLLED STUDY; CYTOPLASM; DEPOLARIZATION; GENE DELETION; GENE MUTATION; GENETIC TRANSFECTION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN TARGETING; SENSITIVITY ANALYSIS;

AMINO ACID SEQUENCE; ANIMALS; CALCIUM; CERCOPITHECUS AETHIOPS; COS CELLS; DOPAMINE; MOLECULAR SEQUENCE DATA; OXIDATIVE STRESS; OXOTREMORINE; PROTEIN STRUCTURE, TERTIARY; RECEPTOR, MUSCARINIC M3; RECEPTORS, MUSCARINIC;

EID: 13844273200     PISSN: 14749718     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1474-9728.2004.00123.x     Document Type: Article

References (47)

1. Bonner TI, Buckley NJ, Young AC, Brann MR (1987) Identification of a family of muscarinic acetylcholine receptor genes. Science 237, 527-532.
2. Bonner TI, Young AC, Brann MR, Buckley NJ (1988) Cloning and expression of the human and rat m5 muscarinic acetylcholine receptor genes. Neuron 1, 403-410.
3. Cheng Y, Wixom P, James-Kracke MR, Sun AY (1994) Effects of extracellular ATP on Fe(2+)-induced cytotoxicity in PC-12 cells. J. Neurochem. 63, 895-902.
4. Claus JJ, Dubois EA, Booij J, Habraken J, de Munck JC, van Herk M, Verbeeten B Jr, vaan Royen EA (1997) Eur. J. Nucl. Med. 24, 602-608.
5. Commenges D, Scotet V, Renaud S, Jacqmin-Gadda H, Barberger-Gateau P, Dartigues JF (2000) Intake of flavonoids and risk of dementia. Eur. J. Epidemiol. 16, 357-363.
6. M GTPase activity in aging and Alzheimer's disease: implications for altered signal transduction. Brain Res. 664, 54-60.
7. De Sarno P, Shestopal SA, King TD, Zmijewska A, Song L, Jope RS (2003) Muscarinic receptor activation protects cells from apoptotic effects of DNA damage, oxidative stress and mitochondrial inhibition. J. Biol. Chem. 278, 11086-11093.
8. Elhusseiny A, Cohen Z, Olivier A, Stanimirovic DB, Hamel E (1999) Functional acetylcholine muscarinic receptor subtypes in human brain microcirculation: identification and cellular localization. J. Cereb. Blood Flow Metab. 19, 794-802.
9. Fawcett JR, Bordayo EZ, Jackson K, Liu H, Peterson J, Svitak A, Frey WH, 2nd (2002) Inactivation of the human brain muscarinic acetylcholine receptor by oxidative damage catalyzed by a low molecular weight endogenous inhibitor from Alzheimer's brain is prevented by pyrophosphate analogs, bioflavonoids and other antioxidants. Brain Res. 950, 10-20.
10. Ferrari-DiLeo G, Mash DC, Flynn DD (1995) Attenuation of muscarinic receptor-G-protein interaction in Alzheimer disease. Mol. Chem. Neuropathol. 24, 69-91.
11. Flynn DD, Ferrari-DiLeo G, Levey AI, Mash DC (1995) Differential alterations in muscarinic receptor subtypes in Alzheimer disease: implications for cholinergic based thereapies. Life Sci. 56, 869-876.
12. Flynn DD, Mash DC (1993) Distinct kinetic binding properties of N-[3H]-methylscopolamine afford differential labeling and localization of M1, M2, and M3 muscarinic receptor subtypes in primate brain. Synapse 14, 283-296.
13. Fornstedt B, Pileblad E, Carlsson A (1990) In vivo autoxidation of dopamine in guinea pig striatum increases with age. J. Neurochem. 55, 655-659.
14. Frey WH, 2nd, Najarian MM, Kumar KS, Emory CR, Menning PM, Frank JC, Johnson MN, Ala TA (1996) Endogenous Alzheimer's brain factor and oxidized glutathione inhibit antagonist binding to the muscarinic receptor. Brain Res. 714, 87-94.
15. 2+ indicators with greatly improved fluorescence properties. J. Biol. Chem. 260, 3440-3450.
16. Hartmann H, Velbinger K, Eckert A, Muller WE (1996) Region-specific downregulation of free intracellular calcium in the aged rat brain. Neurobiol. Aging 17, 557-563.
17. Hastings TG, Lewis DA, Zigmond MJ (1996) Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections. Proc. Natl Acad. Sci. USA 93, 1956-1961.
18. 2+ channel subunit mRNA expression in the hippocampus of aged F344 rats. Neurobiol. Aging 19, 581-587.
19. Hersch SM, Gutekunst CA, Rees HD, Heilman CJ, Levey AI (1994) Distribution of m1-m4 muscarinic receptor proteins in the rat striatum: light and electron microscopic immunocytochemistry using subtype-specific antibodies. J. Neurosci. 5, 3351-3363.
20. Huidobro A, Blanco P, Villalba M, Gomez-Puertas P, Villa A, Pereira R, Bogonez E, Martinez-Serrano A, Aparicio JJ, Satrustegui J (1993) Age-related changes in calcium homeostatic mechanisms in relation with working memory deficiency. Neurobiol. Aging 14, 479-486.
21. Joseph JA, Fisher DR (2003) Muscarinic receptor subtype determines vulnerability to Amyloid beta toxicity in transfected COS-7 cells. J. Alzheimer Dis. 5, 197-208.
22. Joseph JA, Fisher DR, Strain J (2002) Muscarinic receptor subtype determines vulnerability to oxidative stress in COS-7 cells. Free Rad. Biol. Med. 32, 153-161.
23. Joseph JA, Shukitt Hale B, Denisova NA, Martin A, Perry G, Smith MA (2001) Copernicus revisited: amyloid beta in Alzheimer's disease. Neurobiol. Aging 22, 131-146.
24. +-evoked dopamine release from superfused striatal slices: reversals by PBN or Trolox. Free Radic. Biol. Med. 20 821-830.
25. Kaasinen V, Vilkman H, Hietala J, Nagren K, Helenius H, Olsson H, Farde L, Rinne J (2000) Age-related dopamine D2/D3 receptor loss in extrastriatal regions of the human brain. Neurobiol. Aging 21, 683-688.
26. Kaufmann JA, Bickford PC, Taglialatela G (2001) Oxidative-stress-dependent up-regulation of Bcl-2 expression in the central nervous system of aged Fisher-344 rats. J. Neurochem. 76 1099-1108.
27. Ladner CJ, Lee JM (1999) Reduced high-affinity agonist binding at the M (1) muscarinic receptor in Alzheimer disease brain: differential sensitivity to agonists and divalent cations. Exp. Neurol. 158, 451-458.
28. LaVoie MJ, Hastings TG (1999) Dopamine quinone formation and protein modification associated with the striatal neurotoxicity of methamphetamine: evidence against a role for extracellular dopamine. J. Neurosci. 19, 1484-1491.
29. Lee KB, Ptasienski JA, Pals-Rylaarsdam R, Gurevich W, Hosey MM (2000) Arrestin binding to the M (2) muscarinic acetylcholine receptor is precluded by an inhibitory element in the third intracellular loop of the receptor. J. Biol. Chem. 275, 9284-9289.
30. Leslie SW, Chandler LJ, Barr EM, Farrar RP (1985) Reduced calcium uptake by rat brain mitochondria and synaptosomes in response to aging. Brain Res. 329, 177-183.
31. Levey AI (1996) Muscarinic acetylcholine receptor expression in memory circuits: implications for treatment of Alzheimer disease. Proc. Natl Acad. Sci. USA 93, 13541-13546.
32. Lynch DR, Dawson TM (1994) Secondary mechanisms in neuronal trauma. Curr. Opin. Neurol. 7, 510-516.
33. Mattson MP, Culmsee C, Yu ZF (2000) Apoptotic and antiapoptotic mechanisms in stroke. Cell Tissue Res. 301, 173-187.
34. Muma NA, Mariyappa R, Williams K, Lee JM (2003) Differences in regional and subcellular localization of G (q/11) and RGS4 protein levels in Alzheimer's disease: correlation with muscarinic M1 receptor binding parameters. Synapse 47, 58-65.
35. Nakai M, Maeda M (2000) Cerebral cortical muscarinic cholinergic and N-methyl-D-aspartate receptors mediate increase in cortical blood flow elicited by chemical stimulation of periaqueductal gray matter. Neuroscience 98, 449-457.
36. Nyakas C, Oosterink BJ, Keijser J, Felszeghy K, de Jong GI, Korf J, Luiten PG (1997) Selective decline of 5-HT1A receptor binding sites in rat cortex, hippocampus and cholinergic basal forebrain nuclei during aging. J. Chem. Neuroanat. 13, 53-61.
37. Rabinovic AD, Lewis DA, Hastings TG (2000) Role of oxidative changes in the degeneration of dopamine terminals after injection of neurotoxic levels of dopamine. Neuroscience 101, 67-76.
38. Rodriguez-Puertas R, Pascual J, Vilaro T, Pazos A (1997) Autoradiographic distribution of M1, M2, M3, and M4 muscarinic receptor subtypes in Alzheimer Disease. Synapse 26, 341-350.
39. Rossner S, Ueberham U, Schliebs R, Perez-Polo JR, Bigl V (1998) The regulation of amyloid precursor protein metabolism by cholinergic mechanisms and neurotrophin receptor signaling. Prog. Neurobiol. 56, 541-569.
40. Shukitt-Hale B, Mouzakis G, Joseph JA (1998) Psychomotor and spatial memory performance in aging male Fischer 344 rats. Exp. Gerontol. 33, 615-624.
41. Stokes AH, Hastings TG, Vrana KE (1999) Cytotoxic and genotoxic potential of dopamine. J. Neurosci. Res. 55, 659-665.
42. Toescu EC, Verkhratsky A (2000) Parameters of calcium homeostasis in normal neuronal ageing. J. Anat. 197, 563-569.
43. Vannucci RC, Brucklacher RM, Vannucci SJ (2001) Intracellular calcium accumulation during the evolution of hypoxic-ischemic brain damage in the immature rat. Brain Res. Dev. Brain Res. 126, 117-120.
44. Venters HD Jr, Bonilla LE, Jensen T, Garner HP, Bordayo EZ, Najarian MM, Ala TA, Mason RP, Frey WH, 2nd (1997) Heme from Alzheimer's brain inhibits muscarinic receptor binding via thiyl radical generation. Brain Res. 764, 93-100.
45. Wu G, Benovic JL, Hildebrandt JD, Lanier SM (1998) Receptor docking sites for G-protein beta-gamma subunits implications for signal regulation. J. Biol. Chem. 273, 7197-7200.
46. Wu G, Bogatkevich GS, Mukhin YV, Benovic JL, Hildebrandt JD, Lanier SM (2000) Identification of G beta-gamma binding sites in the third intracellular loop of the M (3)-muscarinic receptor and their role in receptor regulation. J. Biol. Chem. 275, 9026-9034.
47. Wu G, Krupnick JG, Benovic JL, Lanier SM (1997) Interaction of arrestins with intracellular domains of muscarinic and alpha2-adrenergic receptors. J. Biol. Chem. 272, 17836-17842.